Want to see GB:DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
69.90 p
-1.05 p(-1.49%)
At close: 4:00 PM EST
69.90 p
-1.05 p(-1.49%)
Day’s Range― - ―
52-Week Range59.15 p - 100.87 p
Previous CloseN/A
Volume189.83K
Average Volume (3M)1.82M
Market Cap
£686.25M
Enterprise Value885.85M
Total Cash (Recent Filing)£180.30M
Total Debt (Recent Filing)£391.40M
Price to Earnings (P/E)28.8
Beta1.55
Next Earnings
Nov 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)0.02
Shares Outstanding967,969,700
10 Day Avg. Volume1,078,739
30 Day Avg. Volume1,820,978
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.68
Price to Sales (P/S)0.79
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£98.33Price Target Upside40.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)£787.68M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationDr. Martens generates strong absolute free cash flow with high conversion versus earnings, giving durable internal funding for capital expenditures, dividends or debt reduction. Reliable FCF supports operational flexibility and lowers reliance on external financing across multiple quarters.
Improving LeverageLeverage has materially improved over several years, reducing refinancing pressure and increasing financial resilience. A falling debt-to-equity trend provides headroom for strategic investments and cushions the business against cyclical retail shocks over the medium term.
Operating Margin RecoveryA meaningful rebound in EBIT margin indicates the company can restore operating profitability through cost control and mix shifts. If sustained, improved operating margins enhance cash generation and the ability to reinvest in DTC retail and brand-building over coming quarters.
Bears Say
Multi-year Revenue DeclineA multi-year revenue contraction signals persistent demand or market-share challenges for core products. Continued top-line decline constrains leverage benefits and makes margin recovery harder, limiting sustainable profit growth unless product or channel trends reverse.
Compressed Margins Versus PeaksMargins remain well below prior peaks, reflecting pricing, cost or mix pressures that have structurally reduced profitability. Even with partial recovery, lower margins reduce free cash flow sustainability and limit long-term returns unless structural drivers are addressed.
Weakened Return On EquityMaterially lower ROE indicates diminished capital efficiency and weaker profit generation on shareholder equity. Persistently low ROE can constrain investor returns and signals that management must improve margins or growth to restore long-term shareholder value.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest share price was 59.15 p and its highest was 100.87 p in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is £686.25M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is Nov 19, 2026 which is in 138 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on May 19, 2026. The company reported 0.042 p earnings per share for the quarter, missing the consensus estimate of 0.044 p by -0.002 p.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc pays a Semiannually dividend of 1.7 p which represents an annual dividend yield of 3.36%. See more information on Dr. Martens Plc dividends here
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is <0.01.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,969,700 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of 0.042 p in its last earnings report, missing expectations of 0.044 p. Following the earnings report the stock price went up 3.266%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in GB:DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£98.33 (40.68% Upside)
£98.33 (40.68% Upside)
Insider Transactions
Sold Shares
Worth £48.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
6.89%
Trailing 12-Months
Asset Growth
-1.40%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
DOCS Stock 12 Month Forecast
Average Price Target
98.33 p
▲(40.68% Upside)
Technical Analysis
Options Prices
Currently, No data available
---